Joan Tabarnero
机构: Saint Louis College
每年引用次数
引用次数
引用: 125,821
H-指数: 144
I10-指数 : 722
出版物: 1,641
Updated survival analysis of EXPERT-C, a randomized phase II trial of neoadjuvant capecitabine and oxaliplatin (CAPOX) and chemoradiotherapy (CRT) with or without cetuximab in MRI-defined high risk rectal cancer patients
I. Chau , F. Sclafani , Bengt Glimelius , D. Gonzalez De Castro
European Journal of Cancer 49
2
2013
TP53 status may predict benefit from cetuximab in high-risk, locally advanced rectal cancer: Results of the EXPERT-C trial
I. Chau , F. Sclafani , B. Glimelius , S.H. Wilson
European Journal of Cancer 49
7
2013
Ibrutinib in combination with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancreatic adenocarcinoma: phase III RESOLVE study.
M. Tempero , D.-T. Waldschmidt , L.M. Coussens , N. Starling
Annals of Oncology 32 ( 5) 600 -608
4
2021
Longitudinal whole-exome sequencing of cell-free DNA for tracking the co-evolutionary tumor and immune evasion dynamics: longitudinal data from a single patient.
D.S. Guttery , J. Tabernero , R.C. Coombes , J.A. Shaw
Annals of Oncology 32 ( 5) 681 -684
2021
P86.03 A Phase 2 Study of Erdafitinib in Patients with Advanced Solid Tumors and Fibroblast Growth Factor Receptor Gene Alterations
C. Massard , M. Schuler , S. Pant , O. Witt
Journal of Thoracic Oncology 16 ( 3)
2021
Management of BRAF-mutant metastatic colorectal cancer: a review of treatment options and evidence-based guidelines.
J. Tabernero , M. Fakih , A. Grothey
Annals of Oncology
40
2021
Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoring.
A. Calles , J. Tabernero , C. Zielinski , M. Piccart
ESMO open 6 ( 3) 100117 -100117
27
2021
Remembering Professor José Baselga
J. Tabernero
ESMO Open
2021
Has COVID-19 had a greater impact on female than male oncologists? Results of the ESMO Women for Oncology (W4O) Survey
M.C. Garassino , J. Tabernero , P. Garrido , S. Peters
ESMO Open 100131
2021
A phase I dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of a novel PI3K inhibitor, XL765, administered orally to patients (pts) with advanced solid tumors
K. P. Papadopoulos , B. Markman , J. Tabernero , A. Patnaik
Journal of Clinical Oncology 26 3510 -3510
25
2008
A phase I, pharmacokinetic (PK) and pharmacodynamic (PD) study of weekly (qW) MK-0646, an insulin-like growth factor-1 receptor (IGF1R) monoclonal antibody (MAb) in patients (pts) with advanced solid tumors
F. Atzori , J. Tabernero , A. Cervantes , M. Botero
Journal of Clinical Oncology 26 3519 -3519
51
2008
A phase II multicenter study evaluating the efficacy and safety of IMC-11F8, a recombinant human IgG1 anti- epidermal growth factor receptor (EGFR) monoclonal antibody (Mab), combined with 5-FU/FA and oxaliplatin (mFOLFOX-6) as first- line therapy
J. Tabernero , J. Sastre Valera , T. Delaunoit , A. Cervantes
Journal of Clinical Oncology 26 4066 -4066
5
2008
Correlation of KRAS status (wild type [wt] vs. mutant [mt]) with efficacy to first-line cetuximab in a study of cetuximab single agent followed by cetuximab + FOLFIRI in patients (pts) with metastatic colorectal cancer (mCRC)
A. Cervantes , T. Macarulla , E. Martinelli , E. Rodriguez-Braun
Journal of Clinical Oncology 26 4129 -4129
19
2008
An economic evaluation of different chemotherapy regimens used in the treatment of advanced colorectal cancer (ACRC) in a Cooperative Group
B. Massuti , A. Abad , A. Antón , E. Aranda
European Journal of Cancer 37 233
2001
Capecitabine in combination with oxaliplatin as first line therapy for patients (pts) with advanced or metastatic colorectal cancer (ACRC): preliminary results of an international multicenter phase II study
C. Twelves , C. Butts , J. Cassidy , Th. Conroy
European Journal of Cancer 37
9
2001
Raltitrexed combined with 5-fluorouracil continuous infusion: a phase I/II dose-escalation trial in advanced solid tumors
B. Massuti , J. Sastre , E. Aranda , J. Tabernero
European Journal of Cancer 37
2001
Phase I study of the novel anticancer drug PM00104 as a 24-hour IV infusion every 3 weeks (q3w) in patients (pts) with advanced solid tumors or lymphoma
J. Capdevila , S. Clive , J. Tabernero , P. Lardelli
Journal of Clinical Oncology 27 2568 -2568
4
2009
Phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of MLN8237, a novel selective aurora A kinase (AAK) inhibitor, in patients (pts) with advanced solid tumors
A. Cervantes-Ruiperez , M. E. Elez , S. Roselló , T. Macarulla
Journal of Clinical Oncology 27 2565 -2565
18
2009
Phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of the selective aurora A kinase (AAK) inhibitor MLN8054 in patients (pts) with advanced solid tumors
T. Macarulla , E. Rodríguez-Braun , J. Tabernero , S. Roselló
Journal of Clinical Oncology 27 2578 -2578
6
2009
A phase I dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics of XL765, a PI3K/TORC1/TORC2 inhibitor administered orally to patients (pts) with advanced solid tumors
P. LoRusso , B. Markman , J. Tabernero , R. Shazer
Journal of Clinical Oncology 27 3502 -3502
38
2009